Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease

BACKGROUND: Alzheimer’s disease is characterized by the deposition of amyloid-beta (Aβ) plaques in the brain. Aβ is produced from the sequential cleavage of amyloid precursor protein by β-site amyloid precursor protein–cleaving enzyme 1 (BACE-1) followed by y-secretase. Verubecestat is an oral BACE-...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:N Engl J Med
Autori principali: Egan, Michael F., Kost, James, Tariot, Pierre N., Aisen, Paul S., Cummings, Jeffrey L., Vellas, Bruno, Sur, Cyrille, Mukai, Yuki, Voss, Tiffini, Furtek, Christine, Mahoney, Erin, Mozley, Lyn Harper, Vandenberghe, Rik, Mo, Yi, Michelson, David
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6776074/
https://ncbi.nlm.nih.gov/pubmed/29719179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1706441
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi